Abivax Stock: price and insider trades · France

Abivax, classified in the Healthcare & Pharma sector, is a listed company based in Paris, France. Its insiders report their share dealings to AMF. From 18 October 2025 to 18 October 2026, the disclosure feed for Abivax logged 21 filings by 9 insiders.

Purchases and sales both appear in the filings: 7 purchases (4 insiders) and 5 sales (3 insiders, €204.5M). No amount is published for 7 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 2 chief executives, 1 board member and 1 senior executive. One trade stands out by size: a sale of €99.8M from Sofinnova Partners SAS, disclosed on 15 January 2026.

The last purchase on record was published on 13 October 2026, which is 4 days ago. Between a trade and the moment it shows up on AMF, the median delay is 3 days. Under the Market Abuse Regulation, managers have three business days to notify their trades.

For context, the typical company on the same exchange (median of 316 companies) published 6 filings over the same period, against 21 filings here. Looking back to 2021, when coverage begins, insiders filed 13 purchases and 21 sales.

In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.